vTv Therapeutics (VTVT) 10-Q13 Nov 152015 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 11, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	VTVT
Entity Registrant Name	vTv Therapeutics Inc.
Entity Central Index Key	1,641,489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Class A Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		9,156,686
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		23,655,814

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 97,010	$ 1,384
Restricted cash and cash equivalents		130
Prepaid expenses and other current assets	799	97
Total current assets	97,809	1,611
Note receivable		6,594
Property and equipment, net	669	3,778
Receivable due from a related party, net		800
Employee loans receivable - related party	48	58
Other long-term assets	1,669	110
Total assets	100,195	12,951
Current liabilities:
Accounts payable and accrued expenses	5,240	3,079
Accounts payable and accrued expenses - related party	516	1,752
Deferred revenue	320
Short-term debt		155
Other liabilities		1,878
Total current liabilities	6,076	6,864
Debt - related party		27,310
Debt, net of current portion		2,110
Fair value of contingent distribution		26,359
Note payable		6,594
Other liabilities, net of current portion	53	4,434
Total liabilities	$ 6,129	$ 73,671
Commitments and contingencies
Redeemable convertible preferred units		$ 438,086
Redeemable noncontrolling interest	$ 188,251
Stockholders'/members' deficit:
Members' deficit		(498,806)
Additional paid-in capital	117,131
Accumulated deficit	(211,645)
Total stockholders' deficit attributable to vTv Therapeutics Inc./members' deficit	(94,185)	(498,806)
Total liabilities, redeemable convertible preferred units, redeemable noncontrolling interest, stockholders' and members' deficit	100,195	$ 12,951
Class A Common Stock [Member]
Stockholders'/members' deficit:
Common stock value	92
Total stockholders' deficit attributable to vTv Therapeutics Inc./members' deficit	92
Class B Common Stock [Member]
Stockholders'/members' deficit:
Common stock value	237
Total stockholders' deficit attributable to vTv Therapeutics Inc./members' deficit	$ 237

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2015$ / sharesshares
Common stock par value \| $ / shares	$ 0.01
Common stock, shares authorized	0
Common stock, shares issued	0
Common stock, shares outstanding	0
Class A Common Stock [Member]
Common stock par value \| $ / shares	$ 0.01
Common stock, shares authorized	100,000,000
Common stock, shares outstanding	9,156,686
Class B Common Stock [Member]
Common stock par value \| $ / shares	$ 0.01
Common stock, shares authorized	100,000,000
Common stock, shares outstanding	23,655,814

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue	$ 133	$ 400	$ 293	$ 615
Operating expenses:
Research and development	6,574	4,037	19,106	12,209
Research and development - related party	585	291	1,532	1,058
General and administrative	2,415	1,592	6,707	9,577
Total operating expenses	9,574	5,920	27,345	22,844
Operating loss	(9,441)	(5,520)	(27,052)	(22,229)
Other loss, net	(1)	(25)	(851)	(11)
Other expense - related party	(56)	(122)	(392)	(466)
Interest income (expense)	4	(33)	(86)	(109)
Interest expense, net - related party	(328)	(170)	(1,667)	(5,562)
Investment loss - related party				(9)
Net loss before income taxes	(9,822)	(5,870)	(30,048)	(28,386)
Income tax provision	0	0	0	0
Net loss before noncontrolling interest	(9,822)	(5,870)	(30,048)	(28,386)
Less: net loss attributable to noncontrolling interest	(5,719)		(5,719)
Net loss attributable to vTv Therapeutics Inc.	$ (4,103)	$ (5,870)	$ (24,329)	$ (28,386)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.49)		$ (3.05)
Weighted-average number of shares of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	8,305,368		7,976,183

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Noncontrolling Interest, Stockholders' and Members' Deficit - (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Units [Member]	Redeemable Noncontrolling Interest [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Members Deficit [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2014	$ (498,806)	$ 438,086				$ (498,806)
Net loss prior to the Reorganization Transactions	(22,111)					(22,111)
Change in redemption value of TTP redeemable convertible preferred units	(75,077)	75,077				(75,077)
Effect of Reorganization Transactions	596,244	$ (513,163)	$ (2,996)		$ 250	$ 595,994
Effect of Reorganization Transaction, shares					25,000,000
Issuance of Class A Common Stock in initial public offering, net of offering costs	104,445			$ 79			$ 104,366
Issuance of Class A common stock in initial public offering, net of offering costs, shares				7,812,500	25,000,000
Net loss subsequent to Reorganization Transactions	(2,218)		(5,719)					$ (2,218)
Share-based compensation recognized subsequent to Reorganization Transactions	304						304
Exchange of Class B Common Stock for Class A Common Stock	12,461		(12,461)	$ 13	$ (13)		12,461
Exchange of Class B Common Stock for Class A Common Stock, shares				1,344,186	(1,344,186)
Change in redemption value of noncontrolling interest	(209,427)		209,427					(209,427)
Ending balance at Sep. 30, 2015	$ (94,185)		$ 188,251	$ 92	$ 237		$ 117,131	$ (211,645)
Ending balance, shares at Sep. 30, 2015	0			9,156,686	23,655,814

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss before noncontrolling interest	$ (30,048)	$ (28,386)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities
Depreciation expense	361	681
Share-based compensation expense	304
Change in fair value of contingent distribution	695
Amortization of debt discount - related party		4,773
Non-cash interest expense-distribution payable	27
Amortization of deferred financing costs		145
Impairment loss on carrying value of land	48
Bad debt expense - related party	(2)	230
Change in fair value of marketable securities - related party		39
Changes in assets and liabilities
Accounts receivable		(144)
Prepaid expenses and other assets	(705)	(68)
Employee loans receivable - related party	12	(32)
Receivable due from a related party		(230)
Note receivable	(20)	(173)
Other long-term assets	(1,594)	(12)
Accounts payable and accrued expenses	1,544	(2,183)
Accounts payable and accrued expenses - related party	2,094	1,484
Deferred revenue	320
Other liabilities	(1,012)	76
Net cash used in operating activities	(27,976)	(23,800)
Cash flows from investing activities
Purchases of property and equipment	(42)	(35)
Net cash used in investing activities	(42)	(35)
Cash flows from financing activities
Proceeds from issuance of vTv Therapeutics Inc. Class A Common Stock sold in initial public offering, net of offering costs	105,773
Payment of offering costs - related party	(1,329)
Proceeds from debt issuance - related party	19,289	23,901
Repayment of debt	(89)	(110)
Net cash provided by financing activities	123,644	23,791
Net increase in cash and cash equivalents	95,626	(44)
Cash and equivalents, beginning of period	1,384	1,089
Cash and equivalents, end of period	97,010	$ 1,045
Non-cash activities:
Change in carrying value of net assets and liabilities not transferred to vTv Therapeutics, LLC as part of the Reorganization Transactions	2,746
Change in redemption value of noncontrolling interest	209,427
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock	$ 12,461

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
Description of Business and Basis of Presentation	Sep. 30, 2015
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Note 1: Description of Business and Basis of Presentation Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”), was incorporated in the state of Delaware in April 2015. The Company was formed to discover and develop orally administered small molecule drug candidates to fill significant unmet medical needs. Initial Public Offering On August 4, 2015, vTv Therapeutics Inc. consummated its initial public offering (“IPO”) of 7,812,500 shares of its Class A common stock, par value $0.01 per share (“Class A Common Stock”) at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. vTv Therapeutics Inc. used the net proceeds of the IPO to acquire nonvoting common units (“vTv Units”) of vTv Therapeutics LLC (“vTv LLC”), an entity created to hold substantially all of the assets and operations of vTvx Holdings I LLC (formerly known as TransTech Pharma, LLC, “TTP” or “vTvx Holdings I”) and vTvx Holdings II LLC (formerly known as High Point Pharmaceuticals, LLC “HPP” or “vTvx Holdings II”), which assets and operations were transferred to such entity in a series of pre-IPO reorganization transactions (the “Reorganization Transactions”). vTv LLC, is an entity under common control with vTv Therapeutics Inc. The Company intends to use the net proceeds from the IPO to fund clinical development, studies, and trials for its various products and other drug candidates, for working capital and other general corporate purposes. Reorganization Transactions During July 2015, TTP and HPP were renamed vTvx Holdings I LLC and vTvx Holdings II LLC, respectively. Concurrent with the IPO, the Company then entered into the following Reorganization Transactions, through which the operations of vTvx Holdings I and vTvx Holdings II were combined into vTv LLC: (1) vTvx Holdings I and vTvx Holdings II contributed substantially all of their assets, including all of their personnel and operations (the “Contributed Assets”), to a newly formed holding company, vTv Therapeutics Holdings LLC (“vTv Therapeutics Holdings”), in return for interests of vTv Therapeutics Holdings. Assets that were not contributed included restricted cash, certain receivables unrelated to the combined operations and land included in property and equipment, net. Liabilities that were not assumed included debt, a contingent distribution payable and other related party liabilities. All assets and liabilities that were not contributed or assumed remained with vTvx Holdings I and vTvx Holdings II and are not reflected in the Condensed Consolidated Balance Sheet as of September 30, 2015 or the Condensed Consolidated Statements of Operations subsequent to August 4, 2015; (2) vTv Therapeutics Holdings contributed the Contributed Assets to vTv LLC, a newly formed Delaware limited liability company, and, for administrative convenience, vTv Therapeutics Holdings directed that the assets be transferred directly to vTv LLC on behalf of vTv Therapeutics Holdings; (3) vTv Therapeutics Inc. amended and restated its certificate of incorporation and by-laws to provide for two classes of common stock: (a) Class A Common Stock, which represents economic interests and has one vote per share, and (b) Class B common stock, par value $0.01 per share, (“Class B Common Stock”), which represents no economic interests and has one vote per share; (4) vTv LLC amended and restated its limited liability company agreement (the “Amended and Restated LLC Agreement”) to provide that it has two classes of membership units: (a) One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC; and (b) Non-voting vTv Units, which represent economic interests; (5) vTv LLC issued the managing member unit to vTv Therapeutics Inc.; (6) vTv LLC issued 25,000,000 vTv Units to vTv Therapeutics Holdings; and (7) vTv Therapeutics Inc. issued 25,000,000 shares of Class B Common Stock, which represents no economic interests in the Company but has the right to cast one vote per share, to vTv Therapeutics Holdings which correspond to each vTv Unit held by vTv Therapeutics Holdings. Below is a summary of the principal documents entered into in connection with the Reorganization Transactions: Exchange Agreement - Tax Receivable Agreement - Investor Rights Agreement - Principles of Consolidation Subsequent to the IPO and the Reorganization Transactions, vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv LLC, the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “ Consolidation As the Reorganization Transactions are considered to be among entities under common control, the Condensed Consolidated Financial Statements for periods prior to the IPO and Reorganization Transactions have been adjusted to combine the historical financial statements of TTP and HPP (which were previously separate entities) for presentation purposes. The historical combined financial statements of these entities include assets and liabilities not transferred to the Company as part of the Reorganization Transactions, as discussed above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2: Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2015, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, Condensed Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit and Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2015 and 2014 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the final prospectus filed by the Company with the SEC on July 31, 2015 relating to the IPO. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations for the three and nine months ended September 30, 2015 and 2014 and cash flows for the nine months ended September 30, 2015 and 2014. The December 31, 2014 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements, but does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2015 and 2014 are unaudited. Interim results are not necessarily indicative of results for an entire year. The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits. The accounts receivable balance at September 30, 2015 was $0. One customer represented 100% of the revenue earned during the three and nine months ended September 30, 2015. Two customers represented 100% of the revenue during the three and nine months ended September 30, 2014. Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Restricted Cash and Cash Equivalents Restricted cash and cash equivalents as of December 31, 2014 reflect cash and cash equivalents that are pledged as collateral required by the terms of operating leases on facilities used by High Point Clinical Trials Center, LLC (“HPCTC”), a wholly-owned subsidiary (prior to December 31, 2014). Collaboration Revenue and Accounts Receivable All of the Company’s collaboration revenue and accounts receivable is related to an exclusive global license agreement (the “License Agreement”), which the Company entered into on March 6, 2015 with Calithera Biosciences, Inc. (“Calithera”), granting Calithera exclusive world-wide rights to research, develop and commercialize the Company’s portfolio of hexokinase II inhibitors. Under the terms of the License Agreement, Calithera will pay the Company an initial license fee of $0.6 million and potential development and regulatory milestone payments totaling up to $30.5 million for the first licensed product, an additional $77.0 million in potential sales-based milestones, as well as royalty payments, based on tiered sales of the first commercialized licensed product. In addition, Calithera will fund up to $1.1 million during the first 12 months of the License Agreement for the costs associated with up to four full-time employees for the Company to develop additional hexokinase inhibitors. If Calithera develops additional licensed products, after achieving regulatory approval of the first licensed product, Calithera would owe additional regulatory milestone payments and additional royalty payments based on sales of such additional licensed products. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. Property and Equipment and other Long-lived Assets The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. During 2014, the Company determined that certain of its land assets met the criteria for held-for-sale accounting treatment and, accordingly, adjusted the carrying value of such assets to the amount of the expected proceeds less costs of disposal, which was lower than the original carrying value. One of these properties was sold during the nine months ended September 30, 2015 and the other properties were not assumed by the Company as part of the Reorganization Transactions. As of December 31, 2014, the carrying value of assets held for sale was $2.8 million. Revenue Recognition The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered. Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer. Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied. Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense. Income Taxes In connection with the IPO, vTv Therapeutics Inc. was formed. From August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships, and all their income and deductions flowed through and were subject to tax at the partner level. As a result of the Reorganization Transactions, vTv Therapeutics Inc. acquired vTv Units and is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC. The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs. The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, include future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Condensed Consolidated Statement of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. Segment and Geographic Information Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment. Share-Based Compensation Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of the awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates. Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the core principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This ASU is effective for fiscal years beginning after December 15, 2017 including interim periods within that reporting period. The Company is currently evaluating the guidance to determine the Company’s adoption method and the effect it will have on the Company’s Condensed Consolidated Financial Statements. In February 2015, the FASB issued ASU 2015-02, “Amendments to the Consolidation Analysis” which significantly change the consolidation analysis required under GAAP and will require companies to reevaluate all previous consolidation conclusions. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company is currently evaluating the impact of this guidance and its impact on the Company’s Condensed Consolidated Financial Statements. In April 2015, the FASB issued ASU No. 2015-05, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” (“ASU 2015-05”). The amendments in this update provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-05 to have a material impact on the Company’s Condensed Consolidated Financial Statements.

Repurchase of Former Officer's

Repurchase of Former Officer's Interest	9 Months Ended
Repurchase of Former Officer's Interest	Sep. 30, 2015
Equity [Abstract]
Repurchase of Former Officer's Interest	Note 3: Repurchase of Former Officer’s Interest On March 28, 2014, TTP entered into a reaffirmation and pledge agreement (“Pledge Agreement”) with a former officer and director (“the Former Officer”) and certain entities related to the officer (collectively with the Former Officer, the “Former Officer and Related Entities”) of TTP. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to TTP in 18,730,276 Series F convertible preferred units of TTP and 9,363,128 Series B convertible preferred units of HPP owned by the Former Officer (the “Pledged Units”) to secure the Former Officer’s obligations to TTP under a promissory note (the “2007 Note”) issued by the Former Officer to TransTech Pharma, Inc., as predecessor in interest to TTP (“TTP Inc.”). See further discussion of the 2007 Note in Note 4. On December 30, 2014, the boards of directors of TTP and HPP authorized a repurchase of units from the Former Officer and Related Entities. The terms of the unit repurchase are stipulated in a Letter Agreement (the “Former Officer Agreement”) with the Former Officer and Related Entities. The Former Officer Agreement superseded all prior understandings with respect to any sales or other similar transactions relating to TTP and HPP, stipulating that these entities would repurchase all of the TTP and HPP’s issued and outstanding units owned by the Former Officer and Related Entities, including any warrants and options to purchase common units. These included 9,100,001 common units of TTP, 14,462,213 common units of HPP, 108,781,071 Series B convertible preferred units of HPP, 218,818,574 Series F convertible preferred units of TTP, 2,776,522 warrants for common units of TTP, 750,000 warrants for common units of HPP and 58,750 options for common units of HPP (collectively, the “Repurchased Units”). All units repurchased by TTP and HPP were legally retired and resumed the status of authorized and unissued common and preferred units. In exchange for the Repurchased Units, under the Former Officer Agreement, TTP and HPP agreed to make periodic cash payments to the Former Officer and Related Entities totaling $7.5 million between December 30, 2014 and September 30, 2017. Payments consisted of $2.5 million paid at closing of the agreement on December 30, 2014 and $5.0 million to be paid in eight equal quarterly installments beginning December 31, 2015. This obligation was recorded in other liabilities in the Condensed Consolidated Balance Sheet as of December 31, 2014. TTP also transferred 100% of its ownership interests in HPCTC to the Former Officer and agreed to make future distributions to the Former Officer (the “Contingent Distributions”). The distributions payable amounts were to be made in the form of cash or certain securities upon the occurrence of certain operational or transactional events and milestones. The Contingent Distributions were reported at fair value on the Condensed Consolidated Balance Sheet and classified as Fair value of contingent distribution as of December 31, 2014. The maximum Contingent Distributions in aggregate equal $150 million. However, TTP and HPP’s obligation to pay the Contingent Distributions would expire upon the occurrence of any one of a number of specified termination events. In addition, the Pledged Units were exchanged for TTP Perpetual Securities in the principal amount of approximately $6.0 million and HPP Perpetual Securities in the principal amount of approximately $0.5 million (the “Perpetual Securities”). All Pledged Units exchanged were legally retired and resumed the status of authorized and unissued preferred units. The Perpetual Securities remained subject to the Pledge Agreement, had no fixed maturity date and accrued interest at a rate per annum equal to the 2007 Note. The Perpetual Securities were able to be prepaid without penalty in whole or in part at any time. Prepayments were to be applied first to accrued interest and then to principal. The Perpetual Securities obligation was presented as a note payable on the Condensed Consolidated Balance Sheet as of December 31, 2014. In conjunction with the issuance of the Perpetual Securities, TTP and HPP gave the Former Officer an irrevocable right to sell back to TTP and HPP all of the Perpetual Securities. This right was exercisable at the discretion of the Former Officer. The exercise price of the put feature for all of the Perpetual Securities was the amount then outstanding on the 2007 Note. The Former Officer also gave TTP and HPP an irrevocable right to repurchase all of the Perpetual Securities. This right was exercisable at the earlier to occur of: (1) the maturity of the 2007 Note or (2) the date the Former Officer receives distribution payable payments under the Former Officer Agreement in excess of $30 million. The exercise price of the call feature for all of the Perpetual Securities was the amount then outstanding on the 2007 Note. TTP and HPP, at their sole discretion, could elect to pay the exercise price in cash or via the extinguishment of the 2007 Note. These obligations and the related rights were not assumed by the Company as part of the Reorganization Transactions discussed in Note 1. On August 28, 2015, vTv Therapeutics Holdings, vTvx Holdings I, vTvx Holdings II, MacAndrews & Forbes Incorporated and M&F entered into a release agreement (the “Release Agreement”) with the Former Officer and Related Entities to settle certain obligations, including the obligation to pay the Contingent Distributions, under the Former Officer Agreement. Under the Release Agreement, vTv Therapeutics Holdings agreed to transfer 1,344,186 shares of Class B Common Stock and the same number of corresponding vTv Units to the Former Officer. Under the Release Agreement and the Former Officer Agreement, the 2007 Note owed by the Former Officer to TTP was also deemed discharged and canceled, and the perpetual securities of vTvx Holdings I and vTvx Holdings II having principal amounts of $6.0 million and $0.5 million, respectively, held by the Former Officer, were repurchased by vTvx Holdings I and vTvx Holdings II in exchange for the discharge of the 2007 Notes. On the same date, under the Exchange Agreement, the Former Officer exchanged those shares of Class B Common Stock and vTv Units for 1,344,186 shares of Class A Common Stock.

Note Receivable

Note Receivable	9 Months Ended
Note Receivable	Sep. 30, 2015
Receivables [Abstract]
Note Receivable	Note 4: Note Receivable On March 30, 2007, TTP Inc. entered into the 2007 Note with the Former Officer, pursuant to which TTP Inc. loaned $4.8 million to the Former Officer. Interest accrued on the 2007 Note at a rate per annum equal to the lowest rate necessary to meet the Internal Revenue Code requirements for the applicable federal rate and is payable at maturity. Under the original terms of the 2007 Note, the entire principal balance and any accrued but unpaid interest would have become due on the earlier of (1) March 30, 2017 or (2) the date on which the Former Officer received in excess of $10 million in proceeds from the sale of any shares of capital stock of TTP, Inc., PharmaCore, Inc. or any of their subsidiaries. See Note 11 for additional discussion of PharmaCore, Inc. As of December 31, 2014, the 2007 Note had an aggregate outstanding principal amount of $4.8 million, and $1.8 million of accrued and unpaid interest. As of September 30, 2015, the 2007 Note had an aggregate outstanding principal amount of $4.8 million, and $1.9 million of accrued and unpaid interest. On March 28, 2014, TTP entered into the Pledge Agreement with the Former Officer. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to TTP in the Pledged Units to secure the Former Officer’s obligations to TTP under the 2007 Note and under the Pledge Agreement. The Pledge Agreement also amended the maturity date of the 2007 Note to be the earlier of March 30, 2018 or the date on which the Former Officer receives in excess of $10 million in proceeds from the sale of any units of TTP, HPP, PharmaCore, Inc. or any of their subsidiaries or from the sale of any assets of any of the foregoing. As discussed in Note 3, on December 30, 2014, TTP exchanged the Pledged Units into the Perpetual Securities. The Perpetual Securities remained subject to the Pledge Agreement, have no fixed maturity date and accrued interest at a rate per annum equal to the 2007 Note. The Perpetual Securities could be prepaid without penalty in whole or in part at any time. Prepayments were first to be applied to accrued interest and then to principal. The Perpetual Securities were initially recorded at their initial fair value of $6.6 million. The increase in the fair value of the perpetual securities during the nine months ended September 30, 2015 was $115 and is reflected in other income, net in the Condensed Consolidated Statements of Operations. This asset and the related rights were not contributed to the Company as part of the Reorganization Transactions discussed in Note 1.

Debt Obligations

Debt Obligations	9 Months Ended
Debt Obligations	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Obligations	Note 5: Debt Obligations In June 2008, TTP Inc. entered into a promissory note with a financial institution secured by a deed of trust on land purchased in 2008. TTP Inc. borrowed $2.8 million at an interest rate of 6.5% per annum. The note principal was to be repaid in one installment on June 20, 2011, with interest payments made monthly during the term of the note. On May 9, 2011, TTP Inc. entered into a Debt Modification Agreement to amend the terms of the promissory note, whereby it extended the maturity date to May 20, 2016 and changed the annual interest rate to the Prime Rate plus 1.250%, with a maximum interest rate of 6.750% and minimum rate of 4.750%. The note is to be repaid in 60 monthly payments of principal and interest, including 59 payments of approximately $22 plus a final payment for the remaining balance of principal and interest. On March 28, 2014, TTP, HPP and M&F agreed to exchange all $116.2 million of outstanding principal and interest due to M&F under the Note and Equity Issuance Agreement (including amounts advanced under the initial agreement plus the 2013 Promissory Notes and amounts advanced following the December 24, 2013 amendment) for 292,722,844 Series F redeemable convertible preferred units of TTP and 155,219,376 Series B redeemable convertible preferred units of HPP. Concurrently on March 28, 2014, TTP and HPP entered into an Uncommitted Advance Agreement with M&F and the Former Officer. As of December 30, 2014, the Former Officer was no longer party to this agreement. Advances made under the Uncommitted Advance Agreement were secured by substantially all of TTP and HPP’s assets and bore interest at an annual rate of LIBOR plus 10%. Principal and interest were originally payable on demand. On May 4, 2015, M&F agreed to extend the maturity date of the Uncommitted Advance Agreement to January 15, 2016. Prepayments could be made under the Uncommitted Advance Agreement without penalty. As of December 31, 2014, $27.3 million of principal was outstanding under the Uncommitted Advance Agreement. Obligations under the Uncommitted Advance Agreement and the promissory note were not assumed by the Company as part of the Reorganization Transactions discussed in Note 1.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Note 6: Share-Based Compensation In conjunction with the IPO, the Board of Directors and sole stockholder adopted a long-term equity incentive plan, the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (the “Plan”), which provides for the grant of cash and cashless exercise stock options, restricted stock awards, restricted stock units and stock appreciation rights to management, other key employees and consultants and non-employee directors on terms and subject to conditions as established by the Compensation Committee of the Board of Directors or certain of the committee’s designees. In settlement of its obligations under this plan, the Company will issue new shares of Class A Common Stock. During the three and nine months ended September 30, 2015, the Company has issued non-qualified stock option awards to certain employees, non-employees and directors of the Company. For the three and nine months ended September 30, 2015, the Company recognized $0.3 million of compensation expense related to share-based awards. As of September 30, 2015, the Company had total unrecognized stock-based compensation expense of approximately $6.9 million, which is expected to be recognized over a weighted average period of 2.9 years. All of the awards granted during the three and nine months ended September 30, 2015 were out-of-the-money at September 30, 2015 and as such the aggregate intrinsic value of these awards was $0. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the three and nine months ended September 30, 2015: Expected volatility 83.83% - 84.06% Expected life of option, in years 5.8 - 6.0 Risk-free interest rate 1.72% - 1.82% Expected dividend yield 0.00% The following table summarizes the activity related to the stock option awards for the three and nine months ended September 30, 2015: Number of Weighted- Awards outstanding at December 31, 2014 — Granted 833,934 $ 8.73 Forfeited (2,000 ) $ 6.56 Awards outstanding at September 30, 2015 831,934 $ 8.73

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7: Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings. Columbia University Agreement In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments at a single digit royalty rate based on net sales of licensed products as defined in the agreement.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity	Note 8: Stockholders’ Equity On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A Common Stock, 100,000,000 shares of Class B Common Stock and 50,000,000 shares of preferred stock, par value $0.01 per share. Holders of Class A Common Stock and Class B Common Stock are entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A Common Stock and Class B Common Stock vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B Common Stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B Common Stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B Common Stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	9 Months Ended
Redeemable Noncontrolling Interest	Sep. 30, 2015
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	Note 9: Redeemable Noncontrolling Interest The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 72.1% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The redeemable noncontrolling interest is recognized at the higher of (1) the its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2015, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $188.2 million.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 10: Fair Value of Financial Instruments The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities, approximate fair value due to their short-term nature. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2014: Balance at Quoted Significant Significant TTP Redeemable preferred securities (a) $ 412,085 $ — $ — $ 412,085 HPP Redeemable preferred securities (a) — — — — Debt (b) 29,575 — 29,575 — Consideration payable (c) 4,897 — — 4,897 Note payable (d) 6,594 — — 6,594 Contingent distribution (a) 26,359 — — 26,359 Total $ 479,510 $ — $ 29,575 $ 449,935 (a) The equity fair value was allocated using the option pricing method (“OPM”). The value of equity was determined using a discounted cash flow (“DCF”) method and adjusted for any applicable separate components of the value such as net operating loss carryforwards, excess or deficit working capital, and fair value of debt instrument. (b) Debt was valued using a yield method, (an income valuation method) for debt securities and a probability-weighted framework based on the expected cash flows to the debt securities under various exit scenarios discounted by the risk-adjusted discount rates. (c) The net present value (“NPV”) of the consideration payable was valued using the DCF method. (d) The note payable was valued using a lattice model. Changes in Level 3 Instruments for the nine months ended September 30, 2015 Balance at Net Change in Net change in (1) Purchases / Sales / Effect of Balance at TTP Redeemable preferred units $ 412,085 $ — $ 66,379 $ — $ — $ (478,464 ) $ — HPP Redeemable preferred units — — — — — — — Consideration payable 4,897 — — — — (4,897 ) — Note payable 6,594 115 — — — (6,709 ) — Contingent distribution 26,359 — 695 — — (27,054 ) — Total $ 449,935 $ 115 $ 67,074 $ — $ — $ (517,124 ) $ — (1) The above represents the change in the fair value of the Company’s redeemable preferred units. See the Condensed Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit for additional changes in the carrying value of the Company’s redeemable preferred units. There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the nine months ended September 30, 2015.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
Related-Party Transactions	Sep. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Note 11: Related-Party Transactions PharmaCore, Inc. Certain controlling stockholders of the Company also control PharmaCore, Inc. (“PharmaCore”). The Company purchases chemistry and Good Manufacturing Practices manufacturing services from PharmaCore. As such, PharmaCore is considered to be a related party. Total purchases from PharmaCore for the nine months ended September 30, 2015 and September 30, 2014 were $1.5 million and $1.1 million, respectively. On April 17, 2007, the Company’s Board of Directors approved $2.0 million of subordinated financing to be provided to PharmaCore. Advances were made and interest accrued before the Company entered into the Subordinated Promissory Note agreement (the “Note Agreement”) with PharmaCore on June 9, 2008. The Note Agreement was amended on April 23, 2010 to provide an additional $2.9 million of subordinated financing, with the same terms as the original note. The Note Agreement has a nine-year term, a fixed interest rate of 8.25% per annum, with maturity of June 1, 2017. No payments were required through December 31, 2014 with accrued interest capitalized into the principal balance. Thereafter, interest is to be paid quarterly. As part of the agreement, the Company received a warrant, exercisable for up to ten years, to purchase 370,370 common units of PharmaCore at an exercise price of $0.54 per unit. During the nine months ended September 30, 2015 and 2014, the Company recorded interest income of $0.4 million related to this financing. This receivable balance was not contributed to the Company as part of the Reorganization Transactions. The total receivable balance due from PharmaCore financing, accrued interest and cash advance activities was $9.6 million at December 31, 2014. As of December 31, 2014, the Company had recorded an allowance for uncollectible amounts related to the PharmaCore receivable $8.8 million. These outstanding balances were not transferred to the Company as part of the Reorganization Transactions. The changes in the allowance during the nine months ended September 30, 2015 (prior to the Reorganization Transactions) and September 30, 2014 are reflected in other income (expense) - related party within the Condensed Consolidated Statements of Operations. MacAndrews & Forbes Incorporated Subsequent to the Reorganization Transactions (Note 1), affiliates of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly control 23,655,814 shares of Class B Common Stock held by vTv Therapeutics Holdings. Further, MacAndrews holds 1,870,666 shares of the Company’s Class A Common Stock as of September 30, 2015. As a result, MacAndrews’ holdings represent approximately 77.8% of the combined voting power of the Company’s outstanding common stock. The Company has entered into several agreements with MacAndrews or its affiliates as part of the Reorganization Transactions as further detailed below and in Note 1: Exchange Agreement Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A Common Stock as determined pursuant to the Exchange Agreement), at the option of vTv Therapeutics Inc. (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire Board of Directors. As of September 30, 2015, MacAndrews has not exchanged any shares under the provisions of this agreement. On October 5, 2015, vTv Therapeutics Holdings was dissolved, and various holders of Class B Common Stock became parties to the Exchange Agreement. Tax Receivable Agreement The Tax Receivable Agreement among the Company, vTv Therapeutics Holdings and M&F provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2015. Investor Rights Agreement The Company entered into the Investor Rights Agreement with vTv Therapeutics Holdings. The Investor Rights Agreement provides vTv Therapeutics Holdings with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides vTv Therapeutics Holdings with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, vTv Therapeutics Holdings is initially entitled to nominate a majority of the members of the Company’s Board of Directors and designate the members of the committees of the Board of Directors. On October 5, 2015, vTv Therapeutics Holdings was dissolved, and M&F became the successor to vTv Therapeutics Holdings pursuant to the terms of the Investor Rights Agreement. Letter Agreement for Reimbursement of Fees and Expenses The Company entered into an agreement with an affiliate of MacAndrews in which it agreed to reimburse MacAndrews or its affiliates for certain out of pocket fees and expenses advanced by affiliates of MacAndrews in connection with the IPO. During the three and nine months ended September 30, 2015, the Company remitted payments to MacAndrews or its affiliates of $1.3 million for such expenses.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 12: Income Taxes As a result of the IPO, the Company is subject to U.S. federal income taxes as well as state taxes. As a result of the Company’s operating losses, the Company did not record an income tax expense for the period ended September 30, 2015. Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 34% is due to the valuation allowance against the Company’s expected net operating losses. As discussed in Note 1, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As there have been no transactions which have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2015.

Net Earnings (Loss) per Unit

Net Earnings (Loss) per Unit	9 Months Ended
Net Earnings (Loss) per Unit	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Earnings (Loss) per Unit	Note 13: Net Earnings (Loss) per Unit Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Loss per share is not presented for the three and nine months ended September 30, 2014 as the Company did not have any economic interests prior to the date of the IPO and Reorganization Transactions through which it was given ownership in vTv LLC. Losses prior to the IPO and Reorganization Transactions would have been allocated to the original members of TTP and HPP. Loss per share for the three and nine months ended September 30, 2015 includes the losses recognized both prior and subsequent to the IPO and Reorganization Transactions. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows: Three months ended Nine months ended 2015 2015 Numerator: Net loss $ (9,822 ) $ (30,048 ) Less: Net loss attributable to non-controlling interests (5,719 ) (5,719 ) Net loss attributable to vTv Therapeutics Inc., basic and diluted $ (4,103 ) $ (24,329 ) Denominator: Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted 8,305,368 7,976,183 Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted $ (0.49 ) $ (3.05 ) For the three and nine months ended September 30, 2015, 831,934 stock options, were excluded from the calculation of diluted loss per share because the effect of their inclusion would have been antidilutive. Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock. However, the 23,655,814 outstanding shares of Class B Common Stock were determined to be antidilutive for the three and nine months ended September 30, 2015. Therefore, they are not included in the computation of net loss per share.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 14: Subsequent Events On October 1, 2015, vTvx Holdings I and vTvx Holdings II merged with and into vTv Therapeutics Holdings, with vTv Therapeutics Holdings continuing as the surviving limited liability company. On October 5, 2015, vTv Therapeutics Holdings was dissolved and made a liquidating distribution of shares of Class B Common Stock and the corresponding vTv Units to its members. As a result of the dissolution, M&F became the successor to vTv Therapeutics Holdings under the Investor Rights Agreement and the Exchange Agreement pursuant to the terms of the Investor Rights Agreement and Exchange Agreement, respectively, and various other holders of Class B Common Stock became parties to the Exchange Agreement.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2015, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, Condensed Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit and Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2015 and 2014 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the final prospectus filed by the Company with the SEC on July 31, 2015 relating to the IPO. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations for the three and nine months ended September 30, 2015 and 2014 and cash flows for the nine months ended September 30, 2015 and 2014. The December 31, 2014 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements, but does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2015 and 2014 are unaudited. Interim results are not necessarily indicative of results for an entire year. The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits. The accounts receivable balance at September 30, 2015 was $0. One customer represented 100% of the revenue earned during the three and nine months ended September 30, 2015. Two customers represented 100% of the revenue during the three and nine months ended September 30, 2014.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents Restricted cash and cash equivalents as of December 31, 2014 reflect cash and cash equivalents that are pledged as collateral required by the terms of operating leases on facilities used by High Point Clinical Trials Center, LLC (“HPCTC”), a wholly-owned subsidiary (prior to December 31, 2014).
Collaboration Revenue and Accounts Receivable	Collaboration Revenue and Accounts Receivable All of the Company’s collaboration revenue and accounts receivable is related to an exclusive global license agreement (the “License Agreement”), which the Company entered into on March 6, 2015 with Calithera Biosciences, Inc. (“Calithera”), granting Calithera exclusive world-wide rights to research, develop and commercialize the Company’s portfolio of hexokinase II inhibitors. Under the terms of the License Agreement, Calithera will pay the Company an initial license fee of $0.6 million and potential development and regulatory milestone payments totaling up to $30.5 million for the first licensed product, an additional $77.0 million in potential sales-based milestones, as well as royalty payments, based on tiered sales of the first commercialized licensed product. In addition, Calithera will fund up to $1.1 million during the first 12 months of the License Agreement for the costs associated with up to four full-time employees for the Company to develop additional hexokinase inhibitors. If Calithera develops additional licensed products, after achieving regulatory approval of the first licensed product, Calithera would owe additional regulatory milestone payments and additional royalty payments based on sales of such additional licensed products. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.
Property and Equipment and other Long-lived Assets	Property and Equipment and other Long-lived Assets The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. During 2014, the Company determined that certain of its land assets met the criteria for held-for-sale accounting treatment and, accordingly, adjusted the carrying value of such assets to the amount of the expected proceeds less costs of disposal, which was lower than the original carrying value. One of these properties was sold during the nine months ended September 30, 2015 and the other properties were not assumed by the Company as part of the Reorganization Transactions. As of December 31, 2014, the carrying value of assets held for sale was $2.8 million.
Revenue Recognition	Revenue Recognition The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered. Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer. Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied. Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense.
Income Taxes	Income Taxes In connection with the IPO, vTv Therapeutics Inc. was formed. From August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level. As a result of the Reorganization Transactions, vTv Therapeutics Inc. acquired vTv Units and is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC. The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs. The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, include future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Condensed Consolidated Statement of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.
Share-Based Compensation	Share-Based Compensation Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of the awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the core principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This ASU is effective for fiscal years beginning after December 15, 2017 including interim periods within that reporting period. The Company is currently evaluating the guidance to determine the Company’s adoption method and the effect it will have on the Company’s Condensed Consolidated Financial Statements. In February 2015, the FASB issued ASU 2015-02, “Amendments to the Consolidation Analysis” which significantly change the consolidation analysis required under GAAP and will require companies to reevaluate all previous consolidation conclusions. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company is currently evaluating the impact of this guidance and its impact on the Company’s Condensed Consolidated Financial Statements. In April 2015, the FASB issued ASU No. 2015-05, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” (“ASU 2015-05”). The amendments in this update provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-05 to have a material impact on the Company’s Condensed Consolidated Financial Statements.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
Share-Based Compensation (Tables)	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Assumptions Used to Estimate Fair Value of Stock Option Awards Granted	The fair value of stock options granted was estimated using the following assumptions during the three and nine months ended September 30, 2015: Expected volatility 83.83% - 84.06% Expected life of option, in years 5.8 - 6.0 Risk-free interest rate 1.72% - 1.82% Expected dividend yield 0.00%
Summary of Stock Award Activity for the Period	The following table summarizes the activity related to the stock option awards for the three and nine months ended September 30, 2015: Number of Weighted- Awards outstanding at December 31, 2014 — Granted 833,934 $ 8.73 Forfeited (2,000 ) $ 6.56 Awards outstanding at September 30, 2015 831,934 $ 8.73

Fair Value of Financial Instr23

Fair Value of Financial Instruments (Tables)	9 Months Ended
Fair Value of Financial Instruments (Tables)	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summarizes the Conclusions Reached Regarding Fair Value Measurements	The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2014: Balance at Quoted Significant Significant TTP Redeemable preferred securities (a) $ 412,085 $ — $ — $ 412,085 HPP Redeemable preferred securities (a) — — — — Debt (b) 29,575 — 29,575 — Consideration payable (c) 4,897 — — 4,897 Note payable (d) 6,594 — — 6,594 Contingent distribution (a) 26,359 — — 26,359 Total $ 479,510 $ — $ 29,575 $ 449,935 (a) The equity fair value was allocated using the option pricing method (“OPM”). The value of equity was determined using a discounted cash flow (“DCF”) method and adjusted for any applicable separate components of the value such as net operating loss carryforwards, excess or deficit working capital, and fair value of debt instrument. (b) Debt was valued using a yield method, (an income valuation method) for debt securities and a probability-weighted framework based on the expected cash flows to the debt securities under various exit scenarios discounted by the risk-adjusted discount rates. (c) The net present value (“NPV”) of the consideration payable was valued using the DCF method. (d) The note payable was valued using a lattice model. Changes in Level 3 Instruments for the nine months ended September 30, 2015 Balance at Net Change in Net change in (1) Purchases / Sales / Effect of Balance at TTP Redeemable preferred units $ 412,085 $ — $ 66,379 $ — $ — $ (478,464 ) $ — HPP Redeemable preferred units — — — — — — — Consideration payable 4,897 — — — — (4,897 ) — Note payable 6,594 115 — — — (6,709 ) — Contingent distribution 26,359 — 695 — — (27,054 ) — Total $ 449,935 $ 115 $ 67,074 $ — $ — $ (517,124 ) $ — (1) The above represents the change in the fair value of the Company’s redeemable preferred units. See the Condensed Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit for additional changes in the carrying value of the Company’s redeemable preferred units.

Net Earnings (Loss) per Unit (T

Net Earnings (Loss) per Unit (Tables)	9 Months Ended
Net Earnings (Loss) per Unit (Tables)	Sep. 30, 2015
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows: Three months ended Nine months ended 2015 2015 Numerator: Net loss $ (9,822 ) $ (30,048 ) Less: Net loss attributable to non-controlling interests (5,719 ) (5,719 ) Net loss attributable to vTv Therapeutics Inc., basic and diluted $ (4,103 ) $ (24,329 ) Denominator: Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted 8,305,368 7,976,183 Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted $ (0.49 ) $ (3.05 )

Description of Business and B25

Description of Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Aug. 04, 2015USD ($)Vote$ / sharesshares	Sep. 30, 2015USD ($)Vote$ / sharesshares	Jul. 29, 2015$ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from initial public offering \| $		$ 105,773
Common stock par value		$ 0.01
Amended and restated limited liability company agreement	One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC	Non-voting vTv Units, which represent economic interests
Amount of cash savings percentage	85.00%	85.00%
Description of tax receivable agreement		The Tax Receivable Agreement among the Company, vTv Therapeutics Holdings and M&F TTP Holdings LLC (“M&F”) provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Class A Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares		7,812,500
Common stock par value		$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1
Class A Common Stock [Member] \| IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from initial public offering \| $	$ 109,000
Number of shares issued through IPO \| shares	7,812,500
Common stock issued price per share	$ 15
Common stock par value	0.01
Class B Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares		25,000,000
Common stock par value	$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1
vTv Therapeutics LLC Units [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Voting power percentage of one managing member unit	100.00%
Common member unit, share issued \| shares	25,000,000
vTv Therapeutics LLC [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC		72.10%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC		27.90%

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 06, 2015USD ($)	Sep. 30, 2015USD ($)Customer	Sep. 30, 2014Customer	Sep. 30, 2015USD ($)CustomerSegmentProperty	Sep. 30, 2014Customer	Dec. 31, 2014USD ($)
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable		$ 0		$ 0
Number of customers \| Customer		1	2	1	2
Number of properties sold \| Property				1
Carrying value of assets held for sale						$ 2,800,000
Significant interest or penalties incurred related to income taxes				$ 0
Number of reportable segments \| Segment				1
Collaborative Arrangement [Member]
Summary Of Significant Accounting Policies [Line Items]
License fee received	$ 600,000
Potential sales-based milestones based on tiered sales of the first commercialized licensed product	77,000,000
Collaborative Arrangement [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Potential development and regulatory milestone payments for the first licensed product	30,500,000
Additional payments for employee services	$ 1,100,000
Revenue [Member] \| Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		100.00%	100.00%	100.00%	100.00%

Repurchase of Former Officer'27

Repurchase of Former Officer's Interest - Additional Information (Detail)	Aug. 28, 2015USD ($)shares	Sep. 30, 2015USD ($)Installments	Dec. 30, 2014USD ($)shares	Mar. 28, 2014shares
Stock Repurchase Program [Line Items]
Number of quarterly installments \| Installments		8
Distribution payable payments to former officer under the reaffirmation agreement, description		This right was exercisable at the earlier to occur of (1) the maturity of the 2007 Note or (2) the date the Former Officer receives distribution payable payments under the Former Officer Agreement in excess of $30 million.
Maximum [Member]
Stock Repurchase Program [Line Items]
Contingent distributions \| $		$ 150,000,000
Other Liabilities [Member] \| Former Officer and Related Entities [Member]
Stock Repurchase Program [Line Items]
Periodic cash payments to former officer and related entities, Total \| $		7,500,000
Cash payments to former officer and related entities at closing of the agreement \| $			$ 2,500,000
Periodic cash payments to former officer and related entities \| $		5,000,000
TransTech Pharma, LLC (TTP) [Member]
Stock Repurchase Program [Line Items]
Principal amount of perpetual securities \| $		6,000,000
High Point Pharmaceuticals, LLC (HPP) [Member]
Stock Repurchase Program [Line Items]
Principal amount of perpetual securities \| $		$ 500,000
High Point Pharmaceuticals, LLC (HPP) [Member] \| Employee Stock Option [Member]
Stock Repurchase Program [Line Items]
Repurchase of units owned by former officer and related entities			58,750
High Point Pharmaceuticals, LLC (HPP) [Member] \| Former Officer [Member]
Stock Repurchase Program [Line Items]
Percentage of ownership interest transferred		100.00%
Common Stock [Member] \| TransTech Pharma, LLC (TTP) [Member]
Stock Repurchase Program [Line Items]
Repurchase of units owned by former officer and related entities			9,100,001
Common Stock [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member]
Stock Repurchase Program [Line Items]
Repurchase of units owned by former officer and related entities			14,462,213
Outstanding Warrants on Common Units [Member] \| TransTech Pharma, LLC (TTP) [Member]
Stock Repurchase Program [Line Items]
Repurchase of units owned by former officer and related entities			2,776,522
Outstanding Warrants on Common Units [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member]
Stock Repurchase Program [Line Items]
Repurchase of units owned by former officer and related entities			750,000
Release Agreement [Member] \| vTvx Holdings I [Member]
Stock Repurchase Program [Line Items]
Principal amount of notes and securities repurchased \| $	$ 6,000,000
Release Agreement [Member] \| vTvx Holdings II [Member]
Stock Repurchase Program [Line Items]
Principal amount of notes and securities repurchased \| $	$ 500,000
Series F Redeemable Convertible Preferred Units [Member] \| TransTech Pharma, LLC (TTP) [Member]
Stock Repurchase Program [Line Items]
Convertible preferred units surrendered by former officer				18,730,276
Repurchase of units owned by former officer and related entities			218,818,574
Series B Redeemable Convertible Preferred Units [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member]
Stock Repurchase Program [Line Items]
Convertible preferred units surrendered by former officer				9,363,128
Repurchase of units owned by former officer and related entities			108,781,071
Class B Common Stock [Member] \| Release Agreement [Member]
Stock Repurchase Program [Line Items]
Number of shares or units transferred	1,344,186
vTv Units [Member] \| Release Agreement [Member]
Stock Repurchase Program [Line Items]
Number of shares or units transferred	1,344,186
Class A Common Stock [Member] \| Release Agreement [Member]
Stock Repurchase Program [Line Items]
Number of shares of Class B common stock exchanged for shares of Class A common stock	1,344,186

Note Receivable - Additional In

Note Receivable - Additional Information (Detail) - USD ($)	9 Months Ended		12 Months Ended
Note Receivable - Additional Information (Detail) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 30, 2014	Mar. 30, 2007
Accounts, Notes, Loans and Financing Receivable [Line Items]
Increase in fair value of perpetual securities	$ (12,000)	$ 32,000
Perpetual Securities [Member] \| TransTech Pharma, LLC (TTP) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Initial fair value of securities recorded				$ 6,600,000
Increase in fair value of perpetual securities	115,000
Former Officer [Member] \| 2007 Note [Member] \| TransTech Pharma, LLC (TTP) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable due from a related party, net	$ 4,800,000		$ 4,800,000		$ 4,800,000
Maturity date of principal balance and unpaid interest	Mar. 30, 2017
Accrued and unpaid interest	$ 1,900,000		$ 1,800,000
Former Officer [Member] \| Minimum [Member] \| TransTech Pharma, LLC (TTP) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from sale of common stock to determine accrued interest and principal due	$ 10,000,000

Debt Obligations - Additional I

Debt Obligations - Additional Information (Detail) - Promissory Note [Member] $ in Thousands	May. 04, 2015	Mar. 28, 2014USD ($)shares	May. 09, 2011	Sep. 30, 2015USD ($)Installments	Dec. 31, 2014USD ($)
TransTech Pharma, LLC (TTP) [Member]
Debt Instrument [Line Items]
Amount borrowed				$ 2,800
Debt instrument, interest rate				6.50%
Debt instrument, principal installment repayment date				Jun. 20, 2011
Description of payment of principal installments				The note principal was to be repaid in one installment on June 20, 2011, with interest payments made monthly during the term of the note.
Debt instrument, maturity date			May 20, 2016
Debt instrument, minimum interest rate			4.75%
Debt instrument, maximum interest rate			6.75%
Debt instrument, repayment of principal and interest, number of installments \| Installments				60
Debt instrument, repayment of principal and interest, number of equal installments \| Installments				59
Debt instrument, monthly installment of principal and interest				$ 22
Debt instrument, number of payment for remaining balance \| Installments				1
Debt instrument periodic payment term				The note is to be repaid in 60 monthly payments of principal and interest, including 59 payments of approximately $22 plus a final payment for the remaining balance of principal and interest.
TransTech Pharma, LLC (TTP) [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, spread on interest rate			1.25%
M&F TTP Holdings LLC [Member] \| Note and Equity Issuance Agreement [Member]
Debt Instrument [Line Items]
Outstanding principal and interest due		$ 116,200
M&F TTP Holdings LLC [Member] \| Uncommitted Advance Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Jan. 15, 2016
Debt instrument, principal amount outstanding					$ 27,300
M&F TTP Holdings LLC [Member] \| TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member] \| Uncommitted Advance Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument, spread on interest rate		10.00%
M&F TTP Holdings LLC [Member] \| Series F Redeemable Convertible Preferred Units [Member] \| TransTech Pharma, LLC (TTP) [Member] \| Note and Equity Issuance Agreement [Member]
Debt Instrument [Line Items]
Redeemable convertible preferred units, issued \| shares		292,722,844
M&F TTP Holdings LLC [Member] \| Series B Redeemable Convertible Preferred Units [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member] \| Note and Equity Issuance Agreement [Member]
Debt Instrument [Line Items]
Redeemable convertible preferred units, issued \| shares		155,219,376

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)
Share-based Compensation [Abstract]
Compensation expense related to share-based awards	$ 0.3	$ 0.3
Unrecognized compensation cost related to non-vested share-based compensation arrangements	6.9	$ 6.9
Weighted average period to recognize unrecognized share-based compensation cost		2 years 10 months 24 days
Aggregate intrinsic value of Share Based Compensation Awards	$ 0	$ 0

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	83.83%	83.83%
Expected life of option, in years	5 years 9 months 18 days	5 years 9 months 18 days
Risk-free interest rate	1.72%	1.72%
Maximum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	84.06%	84.06%
Expected life of option, in years	6 years	6 years
Risk-free interest rate	1.82%	1.82%

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares awards outstanding, Beginning balance	0
Number of shares, Granted	833,934
Number of shares, Forfeited	(2,000)
Number of shares awards outstanding, Ending balance	831,934
Weighted-average grant date fair value, Beginning balance \| $ / shares	$ 0
Weighted-average grant date fair value, Granted \| $ / shares	8.73
Weighted-average grant date fair value, Forfeited \| $ / shares	6.56
Weighted-average grant date fair value, Ending balance \| $ / shares	$ 8.73

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Columbia University [Member] - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	May. 31, 2015	Sep. 30, 2015
Commitments And Contingencies [Line Items]
Annual fee obligated to pay under the agreement	$ 0.1
Annual fee payment obligation period		From 2015 through 2021
Potential regulatory milestone payment	$ 0.8

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail)	Aug. 04, 2015Vote$ / shares	Sep. 30, 2015Vote$ / sharesshares	Jul. 29, 2015$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized		0
Common stock par value \| $ / shares		$ 0.01
Preferred stock, shares authorized			50,000,000
Preferred stock par value \| $ / shares			$ 0.01
Common stock, voting rights		Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
Class A Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized		100,000,000	100,000,000
Common stock par value \| $ / shares		$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1
Class B Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized		100,000,000	100,000,000
Common stock par value \| $ / shares	$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1

Redeemable Noncontrolling Int35

Redeemable Noncontrolling Interest - Additional Information (Detail) $ in Millions	Aug. 04, 2015Vote	Sep. 30, 2015USD ($)Vote
Noncontrolling Interest [Line Items]
Redemption amount of noncontrolling interest		$ 188.2
Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Number of days used to determine exchange value based on weighted average price of Class A common stock		20 days
Common stock, vote per share \| Vote	1	1
vTv Therapeutics LLC [Member] \| Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage		72.10%

Fair Value of Financial Instr36

Fair Value of Financial Instruments - Summary of Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Contingent distribution		$ 26,359
Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	$ 449,935
Net change in fair value included in earnings	115
Net change in fair value	67,074
Purchases/Issuance	0
Sales/Repurchases	0
Effect of Reorganization Transaction	(517,124)
Significant Unobservable inputs (Level 3) [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	412,085
Net change in fair value	66,379
Effect of Reorganization Transaction	(478,464)
Significant Unobservable inputs (Level 3) [Member] \| Contingent Distribution [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	26,359
Net change in fair value	695
Purchases/Issuance	0
Sales/Repurchases	0
Effect of Reorganization Transaction	(27,054)
Significant Unobservable inputs (Level 3) [Member] \| Convertible Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	4,897
Purchases/Issuance	0
Sales/Repurchases	0
Effect of Reorganization Transaction	(4,897)
Significant Unobservable inputs (Level 3) [Member] \| Notes Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	6,594
Net change in fair value included in earnings	115
Purchases/Issuance	0
Sales/Repurchases	0
Effect of Reorganization Transaction	$ (6,709)
Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Debt		29,575
Consideration payable		4,897
Note payable		6,594
Contingent distribution		26,359
Total		479,510
Fair Value, Measurements, Recurring [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Redeemable preferred securities		412,085
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Debt		29,575
Total		29,575
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Consideration payable		4,897
Note payable		6,594
Contingent distribution		26,359
Total		449,935
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable inputs (Level 3) [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Redeemable preferred securities		$ 412,085

Fair Value of Financial Instr37

Fair Value of Financial Instruments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value Disclosures [Abstract]
Fair value equity transfers in and out of level 3 instruments	$ 0
Fair value equity transfers between level 1 and level 2 instruments	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Aug. 04, 2015	Apr. 17, 2007	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Amount of cash savings percentage	85.00%			85.00%
Description of tax receivable agreement				The Tax Receivable Agreement among the Company, vTv Therapeutics Holdings and M&F TTP Holdings LLC (“M&F”) provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Reimbursement of offering costs - related party				$ 1,329,000
PharmaCore, Inc. [Member]
Related Party Transaction [Line Items]
Total purchases from related party				1,500,000	$ 1,100,000
Financing to related party		$ 2,000,000		$ 2,900,000
Note agreement, term				9 years
Note agreement, interest rate				8.25%
Note agreement, maturity date				Jun. 1, 2017
Capitalization of accrued interest						$ 0
Warrant exercisable term				10 years
Shares available under warrant exercised			370,370	370,370
Warrants, Exercise price per unit			$ 0.54	$ 0.54
Interest income recorded				$ 400,000	$ 400,000
Total receivables balance from related party						9,600,000
Allowances for uncollectible amounts from related party						$ 8,800,000
MacAndrews & Forbes Incorporated [Member]
Related Party Transaction [Line Items]
Voting power percentage of one managing member unit				77.80%
Amount of cash savings percentage				85.00%
Description of tax receivable agreement				The Tax Receivable Agreement among the Company, vTv Therapeutics Holdings and M&F provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Reimbursement of offering costs - related party			$ 1,300,000	$ 1,300,000
MacAndrews & Forbes Incorporated [Member] \| Class B Common Stock [Member] \| Vtv Therapeutics Holdings [Member]
Related Party Transaction [Line Items]
Shares held by related party			23,655,814	23,655,814
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party			1,870,666	1,870,666

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 04, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Income tax provision		$ 0	$ 0	$ 0	$ 0
Statutory tax rate				34.00%
Amount of cash savings percentage	85.00%			85.00%

Net Earnings (Loss) per Unit -

Net Earnings (Loss) per Unit - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net loss	$ (9,822)	$ (5,870)	$ (30,048)	$ (28,386)
Less: Net loss attributable to non-controlling interests	(5,719)		(5,719)
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$ (4,103)	$ (5,870)	$ (24,329)	$ (28,386)
Class A Common Stock [Member]
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted	8,305,368		7,976,183
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.49)		$ (3.05)

Net Earnings (Loss) per Unit 41

Net Earnings (Loss) per Unit - Additional Information (Detail) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	831,934	831,934
Class B Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	23,655,814	23,655,814